Think tank: Increased military spending may push up the U.S. deficit and borrowing costs

格隆汇2026/03/16 02:13

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

格隆汇 March 16th｜According to Business Insider, Desmond Lachman, Senior Fellow at the conservative think tank American Enterprise Institute, stated that as the United States is forced to increase military spending in its war with Iran, investors are concerned that the scale of government spending and debt may further spiral out of control and continue to deteriorate. This has reignited market worries about inflation and government debt levels. Lachman said: "The U.S. already had a very poor budget situation when entering this conflict, and now has to significantly increase defense spending, which will only make things worse and put upward pressure on long-term interest rates." He noted that the conflict is likely to last for several weeks. Iran remains determined to maintain its blockade of the Hormuz Strait to drive up oil prices, which means the U.S. military will need at least several weeks to implement plans to open and secure the strait.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)

路透社•2026/10/08 16:11